Novo’s Older GLP-1 Drug Slows Cognitive Decline in Phase IIb Alzheimer’s Trial

Cognitive function in the liraglutide cohort declined 18% slower than in the placebo arm over one year of treatment, researchers announced Tuesday at the Alzheimer’s Association International Conference.